OPV AIDS hypothesis OPV AIDS hypothesis The oral polio vaccine (OPV) AIDS hypothesis posits that the AIDS pandemic originated from live polio vaccines prepared in chimpanzee tissue cultures and then administered to up to one million Africans between 1957 and 1960 in experimental mass vaccination campaigns. Data analyses in molecular biology and phylogenetic studies contradict the OPV AIDS hypothesis; consequently, scientific consensus regards the hypothesis as disproven. The journal "Nature" has described the hypothesis as "refuted". Two vaccines are used throughout the world to combat poliomyelitis. The first polio vaccine, developed by Jonas Salk, is an "inactivated poliovirus vaccine" (IPV), consisting of a
The Immune Response Corporation The Immune Response Corporation The Immune Response Corporation (IRC), founded by Jonas Salk and Kevin Kimberlin and based in Carlsbad, California, pioneered immunotherapeutic products. Francis Crick once said about Salk, “Few have made one discovery that has benefited humanity so greatly. Jonas was a man who, right to his last day, was actively in pursuit of another.” That pursuit was The Immune Response Corporation. Kimberlin “asked Salk to become lead scientific advisor for a new biotech company specializing in ‘anti-idiotypes,’ a novel vaccine technology.” Salk called the proposal “liberating.” The management team included CEO Jim Glavin, former CEO of Genetic